ERBB2 and bone sarcoma: Single angiogenic agents or their combinations have been revealed to be inactive in clinical trials of bone sarcomas [106,107,108], and many potential mutations which are meaningful targets in other malignancies did not work in bone sarcoma; human epidermal growth factor 2 (HER2) is a representative example.